Laboratory monitoring of biologic therapies

John J. Cush, Yusuf Yazici

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The purpose of this report is to provide suggested guidance concerning the monitoring of TNF blocker therapy. Since the completion of randomized trials, several new long-term safety concerns have arisen, involving mycobacterial and opportunistic infections, cytopenias, lymphoma, demyelinating disease, drug-induced lupus, congestive heart failure and hepatotoxicity. Since these serious events are rare, widespread post-marketing use and prolonged follow-up have been required to analyze their prevalence. Monitoring of TNF inhibitors is necessary to reassure physicians and patients of the continued efficacy and safety of these drugs. No published recommendations on monitoring are available The clinician must weigh the potential clinical benefits of TNF inhibition against potential adverse effects. Patients should be evaluated carefully for the risk or presence of infection, tuberculosis and other serious adverse events by regular visits, careful clinical assessments, and an assiduous, high index of suspicion for these rare events. Tuberculin skin testing using PPD is recommended before starting treatment with any TNF inhibitor.

Original languageEnglish (US)
Pages (from-to)S90-S92
JournalClinical and experimental rheumatology
Volume23
Issue number5 SUPPL. 39
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

Biological Therapy
Tuberculin
Safety
Opportunistic Infections
Demyelinating Diseases
Marketing
Pharmaceutical Preparations
Lymphoma
Tuberculosis
Heart Failure
Physicians
Skin
Therapeutics
Infection

Keywords

  • Adverse events
  • Biologics
  • Monitoring
  • Side effects
  • TNF inhibitors

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Laboratory monitoring of biologic therapies. / Cush, John J.; Yazici, Yusuf.

In: Clinical and experimental rheumatology, Vol. 23, No. 5 SUPPL. 39, 01.12.2005, p. S90-S92.

Research output: Contribution to journalArticle

Cush, JJ & Yazici, Y 2005, 'Laboratory monitoring of biologic therapies', Clinical and experimental rheumatology, vol. 23, no. 5 SUPPL. 39, pp. S90-S92.
Cush, John J. ; Yazici, Yusuf. / Laboratory monitoring of biologic therapies. In: Clinical and experimental rheumatology. 2005 ; Vol. 23, No. 5 SUPPL. 39. pp. S90-S92.
@article{f3c55ecbce344b48966da3aae706c482,
title = "Laboratory monitoring of biologic therapies",
abstract = "The purpose of this report is to provide suggested guidance concerning the monitoring of TNF blocker therapy. Since the completion of randomized trials, several new long-term safety concerns have arisen, involving mycobacterial and opportunistic infections, cytopenias, lymphoma, demyelinating disease, drug-induced lupus, congestive heart failure and hepatotoxicity. Since these serious events are rare, widespread post-marketing use and prolonged follow-up have been required to analyze their prevalence. Monitoring of TNF inhibitors is necessary to reassure physicians and patients of the continued efficacy and safety of these drugs. No published recommendations on monitoring are available The clinician must weigh the potential clinical benefits of TNF inhibition against potential adverse effects. Patients should be evaluated carefully for the risk or presence of infection, tuberculosis and other serious adverse events by regular visits, careful clinical assessments, and an assiduous, high index of suspicion for these rare events. Tuberculin skin testing using PPD is recommended before starting treatment with any TNF inhibitor.",
keywords = "Adverse events, Biologics, Monitoring, Side effects, TNF inhibitors",
author = "Cush, {John J.} and Yusuf Yazici",
year = "2005",
month = "12",
day = "1",
language = "English (US)",
volume = "23",
pages = "S90--S92",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "5 SUPPL. 39",

}

TY - JOUR

T1 - Laboratory monitoring of biologic therapies

AU - Cush, John J.

AU - Yazici, Yusuf

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The purpose of this report is to provide suggested guidance concerning the monitoring of TNF blocker therapy. Since the completion of randomized trials, several new long-term safety concerns have arisen, involving mycobacterial and opportunistic infections, cytopenias, lymphoma, demyelinating disease, drug-induced lupus, congestive heart failure and hepatotoxicity. Since these serious events are rare, widespread post-marketing use and prolonged follow-up have been required to analyze their prevalence. Monitoring of TNF inhibitors is necessary to reassure physicians and patients of the continued efficacy and safety of these drugs. No published recommendations on monitoring are available The clinician must weigh the potential clinical benefits of TNF inhibition against potential adverse effects. Patients should be evaluated carefully for the risk or presence of infection, tuberculosis and other serious adverse events by regular visits, careful clinical assessments, and an assiduous, high index of suspicion for these rare events. Tuberculin skin testing using PPD is recommended before starting treatment with any TNF inhibitor.

AB - The purpose of this report is to provide suggested guidance concerning the monitoring of TNF blocker therapy. Since the completion of randomized trials, several new long-term safety concerns have arisen, involving mycobacterial and opportunistic infections, cytopenias, lymphoma, demyelinating disease, drug-induced lupus, congestive heart failure and hepatotoxicity. Since these serious events are rare, widespread post-marketing use and prolonged follow-up have been required to analyze their prevalence. Monitoring of TNF inhibitors is necessary to reassure physicians and patients of the continued efficacy and safety of these drugs. No published recommendations on monitoring are available The clinician must weigh the potential clinical benefits of TNF inhibition against potential adverse effects. Patients should be evaluated carefully for the risk or presence of infection, tuberculosis and other serious adverse events by regular visits, careful clinical assessments, and an assiduous, high index of suspicion for these rare events. Tuberculin skin testing using PPD is recommended before starting treatment with any TNF inhibitor.

KW - Adverse events

KW - Biologics

KW - Monitoring

KW - Side effects

KW - TNF inhibitors

UR - http://www.scopus.com/inward/record.url?scp=33644799488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644799488&partnerID=8YFLogxK

M3 - Article

C2 - 16273791

AN - SCOPUS:33644799488

VL - 23

SP - S90-S92

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 5 SUPPL. 39

ER -